Cargando…

Therapeutic options for management of endometrial hyperplasia

Endometrial hyperplasia (EH) comprises a spectrum of changes in the endometrium ranging from a slightly disordered pattern that exaggerates the alterations seen in the late proliferative phase of the menstrual cycle to irregular, hyperchromatic lesions that are similar to endometrioid adenocarcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chandra, Vishal, Kim, Jong Joo, Benbrook, Doris Mangiaracina, Dwivedi, Anila, Rai, Rajani
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695458/ https://www.ncbi.nlm.nih.gov/pubmed/26463434 http://dx.doi.org/10.3802/jgo.2016.27.e8

Ejemplares similares

Utility and Mechanism of SHetA2 and Paclitaxel for Treatment of Endometrial Cancer
por: Chandra, Vishal, et al.
Publicado: (2021)

Preclinical Efficacy and Involvement of AKT, mTOR, and ERK Kinases in the Mechanism of Sulforaphane against Endometrial Cancer
por: Rai, Rajani, et al.
Publicado: (2020)

Distinct mechanism of cervical cancer cell death caused by the investigational new drug SHetA2
por: Rai, Rajani, et al.
Publicado: (2022)

Histopathologic, Genetic and Molecular Characterization of Endometrial Cancer Racial Disparity
por: Javadian, Pouya, et al.
Publicado: (2021)

Similarities and Differences of Hsp70, hsc70, Grp78 and Mortalin as Cancer Biomarkers and Drug Targets
por: Rai, Rajani, et al.
Publicado: (2021)

Sera Protein Signatures of Endometrial Cancer Lymph Node Metastases
por: Benbrook, Doris Mangiaracina, et al.
Publicado: (2022)

SHetA2 Attack on Mortalin and Colleagues in Cancer Therapy and Prevention
por: Benbrook, Doris Mangiaracina
Publicado: (2022)

Identification of Candidate Biomarker and Drug Targets for Improving Endometrial Cancer Racial Disparities
por: Javadian, Pouya, et al.
Publicado: (2022)

Targeting Wnt Signaling in Endometrial Cancer
por: Fatima, Iram, et al.
Publicado: (2021)

Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2
por: Sharma, Ankur, et al.
Publicado: (2018)

Bioanalytical method development and validation of HPLCUV assay for the quantification of SHetA2 in mouse and human plasma: Application to pharmacokinetics study
por: Sharma, Ankur, et al.
Publicado: (2017)

Dataset on mucin 1 and 4 proteins and SialyT and T antigens staining patterns in cervical cancer primary tumors and metastatic lymph nodes
por: Rai, Rajani, et al.
Publicado: (2023)

Therapeutic options in the treatment of benign prostatic hyperplasia
por: Sandhu, Jaspreet S
Publicado: (2009)

Progestin Resistance and Corresponding Management of Abnormal Endometrial Hyperplasia and Endometrial Carcinoma
por: Lv, Mu, et al.
Publicado: (2022)

Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women
por: Uccella, Stefano, et al.
Publicado: (2022)

The regulation of Hh/Gli1 signaling cascade involves Gsk3β- mediated mechanism in estrogen-derived endometrial hyperplasia
por: Kaushal, Jyoti Bala, et al.
Publicado: (2017)

Impact of DCC (rs714) and PSCA (rs2294008 and rs2976392) Gene Polymorphism in Modulating Cancer Risk in Asian Population
por: Chandra, Vishal, et al.
Publicado: (2016)

Targeting autophagy in cancer management – strategies and developments
por: Ozpolat, Bulent, et al.
Publicado: (2015)

A Case of Cushing's Syndrome Presenting as Endometrial Hyperplasia
por: Lee, Sang Min, et al.
Publicado: (2008)

The value of MRI in management of endometrial hyperplasia with atypia
por: Natarajan, Purushothaman, et al.
Publicado: (2020)

SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres
por: Benbrook, Doris Mangiaracina, et al.
Publicado: (2013)

Conservative treatment for atypical endometrial hyperplasia: what is the most effective therapeutic method?
por: Kim, Mi Kyoung, et al.
Publicado: (2014)

Quantitative assessment of CD44 genetic variants and cancer susceptibility in Asians: a meta-analysis
por: Chandra, Vishal, et al.
Publicado: (2016)

New concepts for an old problem: the diagnosis of endometrial hyperplasia
por: Sanderson, Peter A., et al.
Publicado: (2017)

Emerging Therapeutic Options for the Management of COPD
por: Reid, Debra J., et al.
Publicado: (2013)

Endometrial hyperplasia as a risk factor of endometrial cancer
por: Nees, Lisa K., et al.
Publicado: (2022)

Newer therapeutic options for inherited retinal diseases: Gene and cell replacement therapy
por: Battu, Rajani, et al.
Publicado: (2022)

Complementary Targeting of Rb Phosphorylation and Growth in Cervical Cancer Cell Cultures and a Xenograft Mouse Model by SHetA2 and Palbociclib
por: Kennedy, Amy L., et al.
Publicado: (2020)

Therapeutic Options for the Management of the Cardiorenal Syndrome
por: Koniari, Katerina, et al.
Publicado: (2010)

Management challenges and therapeutic advances in congenital adrenal hyperplasia
por: Mallappa, Ashwini, et al.
Publicado: (2022)

Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management
por: Nwanodi, Oroma
Publicado: (2017)

Modeling effects of diabetes and obesity co-morbidities in endometrial cancer development and progression
por: Benbrook, Doris, et al.
Publicado: (2012)

Non-atypical endometrial hyperplasia: risk factors for occult endometrial atypia and malignancy in patients managed with hysterectomy
por: Hui, Lee Shi, et al.
Publicado: (2021)

Predictive diagnosis of endometrial hyperplasia and personalized therapeutic strategy in women of fertile age
por: Goncharenko, Vadym M, et al.
Publicado: (2013)

Endometrial evaluation with transvaginal ultrasonography for the screening of endometrial hyperplasia or cancer in premenopausal and perimenopausal women
por: Kim, Min-Jeong, et al.
Publicado: (2016)

Fertility-Sparing Approaches in Atypical Endometrial Hyperplasia and Endometrial Cancer Patients: Current Evidence and Future Directions
por: Contreras, Nayanar-Adela, et al.
Publicado: (2022)

Dienogest versus norethisterone acetate in management of endometrial hyperplasia without atypia
por: Girbash, Ehab F., et al.
Publicado: (2023)

Endometrial Stromal Hyperplasia: An Underrecognized Condition
por: Sivridis, Efthimios, et al.
Publicado: (2013)

Genomic imbalance in endometrial hyperplasia and cancer
por: Bednarek, Michal, et al.
Publicado: (2015)

Management of Recurrent Endometrial Cancer or Atypical Endometrial Hyperplasia Patients After Primary Fertility-Sparing Therapy
por: Chen, Junyu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vhlr0eiflk4gok3b2mtqonb1oh